These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 15209903)

  • 1. Monoclonal antibody therapies in transfusion medicine.
    Ouwehand WH; Watkins NA; Garner SF; Smethurst PA
    Vox Sang; 2004 Jul; 87 Suppl 2():151-4. PubMed ID: 15209903
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab--monitoring of antiphospholipid and anti-GP antibodies: a case report.
    Trappe R; Loew A; Thuss-Patience P; Dörken B; Riess H
    Ann Hematol; 2006 Feb; 85(2):134-5. PubMed ID: 16292550
    [No Abstract]   [Full Text] [Related]  

  • 3. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
    Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
    Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
    Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody conjugates and therapeutic strategies.
    McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
    Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
    DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
    Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationization of monoclonal antibodies: another step towards the "magic bullet"?
    Vaisitti T; Deaglio S; Malavasi F
    J Biol Regul Homeost Agents; 2005; 19(3-4):105-12. PubMed ID: 16602624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
    Amadori S; Stasi R
    Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native antibody and antibody-targeted chemotherapy for acute myeloid leukemia.
    Sievers EL
    Adv Pharmacol; 2004; 51():169-83. PubMed ID: 15464909
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
    Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
    Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases.
    Dadachova E; Casadevall A
    Curr Opin Investig Drugs; 2008 Feb; 9(2):184-8. PubMed ID: 18246521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
    Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
    Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of humanized antibodies as cancer therapeutics.
    Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies in the treatment of hematological malignancies].
    Itälä M
    Duodecim; 2002; 118(16):1647-56. PubMed ID: 12271942
    [No Abstract]   [Full Text] [Related]  

  • 17. [Monoclonal anti-CD20 antibody therapy].
    Juhel L; Solal-Celigny P
    Rev Prat; 2004 Apr; 54(7):711-2. PubMed ID: 15253285
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody-based immunotherapy in high-risk neuroblastoma.
    Johnson E; Dean SM; Sondel PM
    Expert Rev Mol Med; 2007 Dec; 9(34):1-21. PubMed ID: 18081947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
    Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
    Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.